Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility.
Jazz Pharmaceuticals Plc (JAZZ)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 1,706,469 | $181,090,490 | 10.72% | |
| 2. | Vestal Point Capital Ryan Wilder | 1,200,000 | $127,344,000 | 6.7% | |
| 3. | Renaissance Technologies Jim Simons | 900,368 | $95,547,052 | -14% | 0.13% |
| 4. | AQR Capital Management Cliff Asness | 794,770 | $84,341,009 | +63% | 0.07% |
| 5. | GMT Capital Thomas E. Claugus | 768,400 | $81,542,608 | +15% | 3.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $103.00 | 1,621 | $166,961.54 | 101,621 | 2025-05-12 | Filing | |
| $99.71 | 100 | $9,971.00 | 100,000 | 2025-05-09 | Filing | |
| $98.91 | 19,216 | $1,900,677.62 | 99,900 | 2025-05-09 | Filing | |
| $98.10 | 80,684 | $7,915,471.55 | 80,684 | 2025-05-09 | Filing | |
| $119.65 | 12,000 | $1,435,800.00 | 27,932 | 2024-03-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $140.00 | 3,500 | $490,000.00 | 408,826 | 2025-10-03 | Filing | |
| $131.78 | 2,000 | $263,560.00 | 412,326 | 2025-10-01 | Filing | |
| $130.00 | 3,000 | $390,000.00 | 429,973 | 2025-09-02 | Filing | |
| $127.23 | 3,000 | $381,690.00 | 432,973 | 2025-09-02 | Filing | |
| $113.21 | 1,000 | $113,210.00 | 435,973 | 2025-08-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 26,800 | $3,532,240 | 2.23% | |
| 2. | 3,600 | $474,480 | 0.06% | |
| 3. | 655 | $86,329 | 0% | |
| 4. | 324 | $42,703 | 0% | |
| 5. | 1 | $131 | 0% |
News See All
13 Stocks With Low Beta That Can Beat Market Volatility
In August, consumer spending and income both exceeded expectations. With the relatively low rate of inflation, companies and consumers are still placing orders for costly products.
Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward trend.
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) continues to advance its mission to transform patient lives through innovative therapies for conditions with limited treatment options.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to "most favored...
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharmaceutical leader, develops and commercializes therapies for complex conditions in oncology, neuroscience, and sleep medicine.
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the best mid-cap stocks with huge upside potential.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...